LabCorp’s Covance Drug Development business has launched a laboratory solution within its functional service provider (FSPx) offering. The acquisition of Chiltern in 2017 substantially expanded the company’s FSP offerings and this newly enlarged service, renamed FSPx, comprises a clinical analytics service and clinical operations capabilities.
 
Clinical analytics now includes Laboratory FSPx, which aims to deliver customized global data solutions that enable clients to better manage laboratory data acquisition, data transfer, data transformation, data reconciliation, and site interactions. Clinical analytics also involves data management, biostatistics and programming, standards, eClinical, technology, and medical writing. Clinical operations include clinical research associates, program managers, program leaders, regulatory staff, clinical trial leads, and clinical trial managers.
 
“Laboratory FSPx helps clients improve data readiness by integrating FSPx and central laboratory data teams from study setup to completion,” said Bill Hanlon, Ph.D., group president, Covance Clinical Development and Commercialization Services. “It also enables faster study start-up by implementing standards, lean processes and blended roles.”

Laboratory FSPx leverages experienced data managers, external data specialists, and clinical programmers to help clinical teams interface with central labs, local labs, and specialty labs including biomarker and pharmacokinetics labs.
 
“Whether it’s reducing the data reconciliation process time or reducing turnaround times for protocol amendments, Laboratory FSPx’s capabilities at Covance provide end-to-end solutions that help clients manage their laboratory operations,” said Paul Kirchgraber, M.D., senior vice president, Clinical Trials. Testing Solutions, Covance. “The Covance FSPx portfolio of capabilities, now including Laboratory FSPx, meets the growing demands of the industry for flexible, best-in-class solutions for clinical research.”